Disposition of amiodarone in rats after single and multiple intra-peritoneal doses

被引:5
作者
Najjar, TAO [1 ]
机构
[1] Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
关键词
amiodarone; pharmacokinetics; disposition; tissues distribution;
D O I
10.1007/BF03192314
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of amiodarone was studied after single and multiple dosing in two groups of male Wistar and Albino rats. The first group (40 rats) received a single intraperitoneal (ip) doseof amiodarone (100 mg/kg) and 4 rats sacrificed 1, 2, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dosing. The second group (42 rats) received amiodarone (50 mg/kg, i.p., daily) for 5 days a week for 5 weeks and 6 rats were sacrificed at 1, 2, 3, 4, 5, 6 and 8 weeks. Rats of both group were sampled for blood, heart, lung and fat and the concentrations of amiodarone in these samples were determined using. The elimination of amiodarone from plasma after single dose followed a biphasic pattern with a terminal half-life of 54.7 +/- 8.2 hours. The concentrations of amiodarone in the tissues were halved within 26.8, 34.9 and 37.45 hours in the heart, lung and fat, respectively. The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 mug/ml, 1.73 mug/mg, 7.61 mug/mg and 29.01 mug/mg, respectively. The concentration of amiodarone after multiple dosing were halved within 8.4, 5.5, 6.4 and 9.8 days, for the plasma, heart, lung and fat, respectively. The average concentrations of amiodarone in plasma, heart, lung and fat during multiple doses were 0.97 mug/mg, 7.63 mug/mg and 65.01 mug/mg respectively. In conclusion, after multiple dosing, the elimination half-life of amiodarone and its fat contents were 3.7 and 2.8 times greater than that after single dosing. The excessive amount of amiodarone observed in fat tissues after multiple dosing is probably the reason for the prolonged elimination half-life. Based on the elimination half-lives data, the time to steady state is about two weeks and the drug should be withheld for less than a mont if a patient required discontinuation because of serious adverse effects.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 50 条
  • [31] INFLUENCE OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF NEFAZODONE AND 2 OF ITS METABOLITES AFTER SINGLE AND MULTIPLE ORAL DOSES
    FERRY, N
    BERNARD, N
    CUISINAUD, G
    ROUGIER, P
    TREPO, C
    SASSARD, J
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1994, 8 (05) : 463 - 473
  • [32] Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects
    Dan Zhang
    Yanan Zhang
    Man Liu
    Xiaolin Wang
    Man Yang
    Jing Han
    Huichen Liu
    European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38 : 209 - 215
  • [33] Pharmacokinetic Study of Frovatriptan Succinate Tablet After Single and Multiple Oral Doses in Chinese Healthy Subjects
    Zheng, Hongquan
    Xia, Yan
    Qu, Shengjun
    Fan, Lin
    Zhang, Jingjing
    Ma, Zhixiang
    Chen, Yangsheng
    Fan, Hongwei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2961 - 2968
  • [34] Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects
    Zhang, Dan
    Zhang, Yanan
    Liu, Man
    Wang, Xiaolin
    Yang, Man
    Han, Jing
    Liu, Huichen
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2013, 38 (03) : 209 - 215
  • [35] Serum and peritoneal exudate concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study
    Leon, Lisa
    Guerci, Philippe
    Pape, Elise
    Thilly, Nathalie
    Luc, Amandine
    Germain, Adeline
    Butin-Druoton, Anne-Lise
    Losser, Marie-Reine
    Birckener, Julien
    Scala-Bertola, Julien
    Novy, Emmanuel
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (01) : 156 - 161
  • [36] Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection
    Eslam, Roza Badr
    Burian, Angela
    Vila, Greisa
    Sauermann, Robert
    Hammer, Alexandra
    Frenzel, Dorothea
    Minichmayr, Iris K.
    Kloft, Charlotte
    Matzneller, Peter
    Oesterreicher, Zoe
    Zeitlinger, Markus
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (09) : 1058 - 1062
  • [37] Brain Iron Distribution after Multiple Doses of Ultra-small Superparamagnetic Iron Oxide Particles in Rats
    Gorman, Andrew W.
    Deh, Kofi M.
    Schwiedrzik, Caspar M.
    White, Julie R.
    Groman, Ernest Victor
    Fisher, Clark A.
    Gillen, Kelly M.
    Spincemaille, Pascal
    Rasmussen, Skye
    Prince, Martin R.
    Voss, Henning U.
    Freiwald, Winrich A.
    Wang, Yi
    COMPARATIVE MEDICINE, 2018, 68 (02) : 139 - 147
  • [38] Disposition of Human Recombinant Lubricin in Naive Rats and in a Rat Model of Post-traumatic Arthritis After Intra-articular or Intravenous Administration
    Yulia Vugmeyster
    Qin Wang
    Xin Xu
    John Harrold
    Daren Daugusta
    Jian Li
    Richard Zollner
    Carl R. Flannery
    Moisés A. Rivera-Bermúdez
    The AAPS Journal, 2012, 14 : 97 - 104
  • [39] Disposition of Human Recombinant Lubricin in Naive Rats and in a Rat Model of Post-traumatic Arthritis After Intra-articular or Intravenous Administration
    Vugmeyster, Yulia
    Wang, Qin
    Xu, Xin
    Harrold, John
    Daugusta, Daren
    Li, Jian
    Zollner, Richard
    Flannery, Carl R.
    Rivera-Bermudez, Moises A.
    AAPS JOURNAL, 2012, 14 (01): : 97 - 104
  • [40] Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels
    Masaomi Takizawa
    Dirk Cerneus
    Ingrid Michon
    Sanne Rijnders
    John Meijer
    Akiyoshi Someya
    Yuichiro Sato
    Advances in Therapy, 2020, 37 : 3967 - 3984